BIOGEN INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
BIOGEN INC. (BIIB) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $6.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-06
- BIOGEN INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $6.60M, a 48.03% decline from fiscal 2024.
- BIOGEN INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $12.70M, a 504.76% increase from fiscal 2023.
- BIOGEN INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $2.10M, a 31.25% increase from fiscal 2022.
- BIOGEN INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $1.60M, a 50.00% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.60M 10-K · filed 2026-02-06 | |
| 2024-12-31 | $12.70M 10-K · filed 2026-02-06 | |
| 2023-12-31 | $2.10M 10-K · filed 2026-02-06 | |
| 2022-12-31 | $1.60M 10-K · filed 2025-02-12 | |
| 2021-12-31 | $3.20M 10-K · filed 2024-02-14 | |
| 2020-12-31 | $7.90M 10-K · filed 2023-02-15 | |
| 2019-12-31 | $100.00K 10-K · filed 2022-02-03 | |
| 2018-12-31 | $2.90M 10-K · filed 2021-02-03 | |
| 2017-12-31 | $1.40M 10-K · filed 2020-02-06 | |
| 2016-12-31 | $1.40M 10-K · filed 2019-02-06 | |
| 2015-12-31 | $1.20M 10-K · filed 2018-02-01 | |
| 2014-12-31 | $1.60M 10-K · filed 2017-02-02 | |
| 2013-12-31 | $1.90M 10-K · filed 2016-02-03 | |
| 2012-12-31 | $1.90M 10-K · filed 2015-02-04 | |
| 2011-12-31 | $2.30M 10-K · filed 2014-02-06 | |
| 2010-12-31 | $3.70M 10-K · filed 2013-02-05 | -$3.70M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |